Evaluate serum GFAP and NfL levels during treatment with complement component 5–inhibitor therapies (C5ITs) eculizumab and ravulizumab in AQP4+ NMOSD.
No takes yet. Share an insight, caveat, or question.
Wingerchuk et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: